Conference Calls, New Appointments, Upcoming Presentations, Prospectus Filings and Acquisition Deal Updates - Research Report on Johnson & Johnson, WellPoint, Regeneron, Onyx, and MannKind

NEW YORK, September 23, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), WellPoint Inc. (NYSE: WLP), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), and MannKind Corporation (NASDAQ: MNKD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report  

On September 17, 2013, Johnson & Johnson (JNJ) announced that the Company will host a conference call for investors to review its Q3 2013 financial results, on October 15, 2013 at 8:30 a.m. ET. The Company informed that Michel Orsinger, Worldwide Chairman of DePuy Synthes Companies, Dominic J. Caruso, Vice President, Finance and CFO, and Louise Mehrotra, Vice President, Investor Relations, will host the call. Interested parties may access the conference call via its website. Also, JNJ informed that the earnings webcast is optimized for mobile streaming on iOS devices, such as the iPhones, iPods, and iPads. In addition, the webcast and podcast replay of the call will be available approximately two hours after the conclusion of the conference call. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/07a8_JNJ]

--

WellPoint Inc. Research Report

On September 17, 2013, WellPoint Inc. (WellPoint) announced the appointment of John Short and Elizabeth (Liz) Tallett to the Company's Board of Directors, effective September 18, 2013 and October 1, 2013, respectively. According to the Company, Ms. Tallett is a Principal of Hunter & Partners, LLC, a health care consulting firm, while Mr. Short is the former CEO of RehabCare Group, a rehabilitation services provider. The Full Research Report on WellPoint Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/64cd_WLP]

--

Regeneron Pharmaceuticals Inc. Research Report    

On September 17, 2013, Regeneron Pharmaceuticals Inc. (Regeneron) announced that it will present the results from Phase 3 VIVID and VISTA trials EYLEA (aflibercept) Injection in Diabetic Macular Edema (DME) at an oral session during the upcoming annual meeting of the Retina Society. The Presentation is scheduled to take place on September 27, 2013 at 4:51 p.m. PDT, in Los Angeles, US. In addition, Regeneron will also present the same data at the EURETINA Congress in Hamburg, Germany on the same day, September 27, 2013 at 3:58 p.m. CEST. The Company further informed that it will host a webcast investor meeting on September 28, 2013 at 7:00 a.m. PDT/10:00 a.m. EDT to discuss the aforementioned data. The Full Research Report on Regeneron Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/8ea7_REGN]

--

Onyx Pharmaceuticals, Inc. Research Report  

On September 18, 2013, Onyx Pharmaceuticals Inc. (Onyx) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Amgen Inc.'s (Amgen) proposed acquisition of Onyx, was terminated on September 18, 2013 by the United States Federal Trade Commission. Earlier, on August 25, 2013, the two companies had announced an agreement under which Amgen would acquire all of the outstanding shares of Onyx for $125 per share in cash, with the transaction to be effected through a tender offer. According to Onyx, the termination of the HSR waiting period satisfies one of the conditions to consummate the tender offer, while other closing conditions are yet to be satisfied, including a minimum tender of at least a majority of outstanding Onyx shares on a fully diluted basis. According to Onyx, the tender offer will expire on October 1, 2013, unless it is extended in accordance with the terms of the merger agreement between the two companies. The Full Research Report on Onyx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/fcf2_ONXX]

--

MannKind Corporation Research Report  

On September 18, 2013, MannKind Corporation's stock advanced 0.49%. The stock fluctuated from $5.78 to $5.95 before ending the day at $5.90. Also, on the same date, the Company filed a Form S3 Registration Statement under the Securities ACT of 1933 with the Securities and Exchange Commission. According to the Company, the said prospectus relates to the sale or disposition from time to time of up to a maximum of 12 million shares of the Company's common stock that may be issued upon conversion of senior secured convertible notes, or Notes, held by Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (selling stockholders). The selling stockholders acquired the Notes from the Company in private placements that closed on July 1, 2013 and September 5, 2013. Mannkind also stated that they are not selling any common stock under the prospectus and will not receive any of the proceeds from the sale of its common stock by the selling stockholders. The Full Research Report on MannKind Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/044e_MNKD]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner